Is Amphastar Pharmaceuticals, Inc. (AMPH) Halal?

NASDAQ Healthcare United States $874M
✗ NOT HALAL
Confidence: 90/100
Amphastar Pharmaceuticals, Inc. (AMPH) is Not Halal under AAOIFI Standard 21. The company's debt ratio of 73.8% exceeds the 30% threshold, indicating excessive interest-bearing debt relative to market capitalization. Amphastar Pharmaceuticals, Inc. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 73.8%
/ 30%
31.8%
/ 30%
18.1%
/ 30%
1.21%
/ 5%
✗ NOT HALAL
DJIM 73.8%
/ 33%
31.8%
/ 33%
18.1%
/ 33%
1.21%
/ 5%
✗ NOT HALAL
MSCI 40.3%
/ 33%
17.4%
/ 33%
9.9%
/ 33%
1.21%
/ 5%
✗ NOT HALAL
S&P 73.8%
/ 33%
31.8%
/ 33%
18.1%
/ 33%
1.21%
/ 5%
✗ NOT HALAL
FTSE 40.3%
/ 33%
17.4%
/ 33%
9.9%
/ 50%
1.21%
/ 5%
✗ NOT HALAL

Financial Highlights

P/E Ratio
9.4
Forward: 5.4
EPS
$2.03
P/B Ratio
1.1
EV/EBITDA
5.6
EV: $1.2B
Revenue
$720M
Growth: -1.8%
Beta
0.9
Average volatility
Current Ratio
4.0

Profitability

Gross Margin 49.5%
Operating Margin 19.4%
Net Margin 13.6%
Return on Equity (ROE) 12.9%
Return on Assets (ROA) 6.4%

Cash Flow & Balance Sheet

Operating Cash Flow$156M
Free Cash Flow$119M
Total Debt$656M
Debt-to-Equity83.2
Current Ratio4.0
Total Assets$1.6B

Price & Trading

Last Close$19.53
50-Day MA$24.08
200-Day MA$25.38
Avg Volume469K
Beta0.9
52-Week Range
$17.03
$31.26

About Amphastar Pharmaceuticals, Inc. (AMPH)

CEO
Dr. Yongfeng Zhang Ph.D.
Employees
1,976
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Exchange
NASDAQ
Market Cap
$874M
Currency
USD

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Amphastar Pharmaceuticals, Inc. (AMPH) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Amphastar Pharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Amphastar Pharmaceuticals, Inc.'s debt ratio?

Amphastar Pharmaceuticals, Inc.'s debt ratio is 73.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 40.3%.

What are Amphastar Pharmaceuticals, Inc.'s key financial metrics?

Amphastar Pharmaceuticals, Inc. has a market capitalization of $874M, trailing P/E ratio of 9.4, and revenue of $720M. The company maintains a gross margin of 49.5% and a net margin of 13.6%. Return on equity stands at 12.9%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.